We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
- Authors
Ntalas, Ioannis V.; Kalantzi, Kallirroi I.; Tsoumani, Maria E.; Bourdakis, Adamantios; Charmpas, Christos; Christogiannis, Zaharias; Dimoulis, Nikolaos; Draganigos, Antonios; Efthimiadis, Ioannis; Giannakoulas, Giorgos; Giatrakos, Ioannis; Giogiakas, Vassilios; Goumas, Giorgos; Hatziathanasiou, Giorgos; Kazakos, Evangelos; Kipouridis, Nikolaos; Konstantinou, Spiros; Milionis, Haralampos; Nikolopoulos, Dimitrios; Peltekis, Leonidas
- Abstract
<bold>Background: </bold>In the present clinical trial, we compared the efficacy and safety of the generic clopidogrel besylate (CB) with the innovator clopidogrel hydrogen sulfate (CHS) salt in patients eligible to receive clopidogrel.<bold>Methods: </bold>A prospective 2-arm, multicenter, open-label, phase 4 clinical trial. Consecutive patients (n = 1864) were screened and 1800 were enrolled in the trial and randomized to CHS or CB. Primary efficacy end point was the composite of myocardial infarction, stroke, or death from vascular causes, and primary safety end point was rate of bleeding events as defined by Bleeding Academic Research Consortium criteria.<bold>Results: </bold>At 12-month follow-up, no differences were observed between CB (n = 759) and CHS (n = 798) in primary efficacy and safety end points (age, sex, history of percutaneous coronary intervention adjusted odds ratio [OR], 0.70; 95% confidence interval [CI], 0.41-1.21 and OR, 0.81; 95% CI, 0.51-1.29, respectively) between CHS and CB. Analyses of efficacy and safety in subgroups that were defined according to the qualifying diagnosis revealed that there was no difference between CHS and CB.<bold>Conclusion: </bold>The efficacy and safety of CB administered for 12 months for the secondary prevention of atherothrombotic events are similar to that of CHS. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE trial; ClinicalTrials.gov Identifier:NCT02126982).
- Subjects
GREECE; CLOPIDOGREL; RANDOMIZED controlled trials; SULFURIC acid; MYOCARDIAL infarction; CORONARY disease; CARDIOVASCULAR disease diagnosis; CARDIOVASCULAR disease related mortality; DISEASE relapse prevention; CARDIOVASCULAR system; CARDIOVASCULAR diseases; CLINICAL trials; COMPARATIVE studies; DOSAGE forms of drugs; GENERIC drugs; HEMORRHAGE; LONGITUDINAL method; RESEARCH methodology; MEDICAL care; MEDICAL cooperation; PHARMACOKINETICS; RESEARCH; STROKE; TICLOPIDINE; TIME; EVALUATION research; TREATMENT effectiveness; KAPLAN-Meier estimator; PLATELET aggregation inhibitors; ODDS ratio; THERAPEUTICS
- Publication
Journal of Cardiovascular Pharmacology & Therapeutics, 2016, Vol 21, Issue 6, p516
- ISSN
1074-2484
- Publication type
journal article
- DOI
10.1177/1074248416644343